Compound ID | 1775
Class: Odilorhabdin
| Spectrum of activity: | Gram-negative |
| Details of activity: | Active against Enterobacteriaceae. Binds to the bacterial ribosome to disrupt protein synthesis |
| Description: | Semisynthetic, derived from Xenorhabdus |
| Institute where first reported: | Nosopharm |
| Year first mentioned: | 2015 |
| Highest development stage: | Preclinical |
| Development status: | Active (as of 2022) |
| External links: | |
| PubChem link: | https://pubchem.ncbi.nlm.nih.gov/compound/121246383 |
| Guide to Pharmacology: | NOSO-502 |
| Citations: |
|
| Patent: | US10626144B2 |